New Approaches to Gastroprotection: Calcium Modulators

  • Gary B. Glavin
  • Arleen M. Hall
Part of the Hans Selye Symposia on Neuroendocrinology and Stress book series (HSSN, volume 2)


Despite impressive developments in gastrointestinal pharmacology over the last several years, the treatment of gastroduodenal disease remains palliative and the search for new therapeutic agents continues. One focus of our investigation has been directed towards calcium modulators and their effects in several animal models of gastric function and pathology.


Gastric Acid Secretion Gastric Secretion Calcium Channel Antagonist Gastric Mucosal Injury Calcium Chelator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    I. Szelenyi, Calcium, histamine and pentagastrin: Speculations about the regulation of gastric acid secretion, Agents Actions. 10:187 (1980).PubMedCrossRefGoogle Scholar
  2. 2.
    K. Sewing, and H. Hannemann, Calcium channel antagonists verapamil and gallopamil are powerful inhibitors of acid secretion in isolated and enriched guinea pig parietal cells, Pharmacology. 27:9 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    E. Aadland, and A. Berstad, Effect of verapamil on basal and pentagastrin-stimulated gastric acid secretion, Clin Pharmacol Ther. 34:399 (1983).CrossRefGoogle Scholar
  4. 4.
    R. Levine, S. Petokas, A. Starr, and R. Eich, Effect of verapamil on basal and pentagastrin-stimulated gastric acid secretion, Clin Pharmacol Ther. 34:399 (1983).PubMedCrossRefGoogle Scholar
  5. 5.
    R. Caldara, E. Masci, C. Barbieri, M. Sorghi, V. Piepoli, and A. Tittobello, A., Effect of nifedipine on gastric acid secretion and gastrin release in healthy man, Eur J Clin Pharmacol. 28:677 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    G. Glavin, Verapamil and nifedipine effects on gastric acid secretion and ulcer formation in rats,J Pharm Pharmacol. 40:514 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    C. Ogle, C. Cho, C., Tong, M., and M. Koo, The influence of verapamil on the gastric effects of stress in rats, Eur. J. Pharmacol. 112:399 (1985).PubMedCrossRefGoogle Scholar
  8. 8.
    R. Wait, A. Leahy, J. Vee, and T. Pollock, Verapamil attenuates stress-induced gastric ulceration,J Surg Res. 38:424 (1985).PubMedCrossRefGoogle Scholar
  9. 9.
    B. Ghanayem, H. Matthews, and R. Maronpot, Calcium channel blockers protect against ethanol-and indomethacin-induced gastric lesions in rats, Gastroenterology. 92:106 (1987).PubMedGoogle Scholar
  10. 10.
    J. Esplugues, R. Brage, J. Cortijo, M. Marti-Bonmati, G. Hernandez, B. Sarria, and J.Esplugues, Differential effects of verapamil on various gastric lesions in rats, Pharmacology. 36:69 (1988).PubMedCrossRefGoogle Scholar
  11. 11.
    M. Koo, C. Cho, and C Ogle, Verapamil worsens ethanol-induced gastric ulcers in rats, Eur. J.Pharmacol. 120:355 (1986).PubMedCrossRefGoogle Scholar
  12. 12.
    G. Glavin, Calcium channel modulators: Effects on gastric function, Eur J Pharmacol. 160:323 (1989).PubMedCrossRefGoogle Scholar
  13. 13.
    G. Glavin, Nitrendipine reduces experimental gastric and duodenal ulceration: Possible role of somatostatin, Dig Dis Sci. 34:1313 (1989).CrossRefGoogle Scholar
  14. 14.
    G. Glavin, and C. Ogle, Adrenalectomy, but not vagotomy, reverses the worsening effect of Ca2+ blockers on ethanol-induced gastric lesions in rats, Eur J Pharmacol. 205:171 (1991).PubMedCrossRefGoogle Scholar
  15. 15.
    G. Glavin, and C. Ogle, Adrenal demedullectomy does not affect the ability of nitrendipine to worsen ethanol-induced gastric lesions, Med Sci Res. 19:405 (1991).Google Scholar
  16. 16.
    M. Koo, C. Cho, and C. Ogle, Luminal acid in stress ulceration and the antiulcer action of verapamil in rat stomachs, J Pharm Pharmacol. 38:845 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    C. Gutierrez-Cabano, Prostaglandins and sulfhydryls mediate gastric protection induced by verapamil in rats, Dig Dis Sci. 38:2043 (1993).PubMedCrossRefGoogle Scholar
  18. 18.
    S. Szabo, J. Trier, and P. Frankel, Sulfhydryl compounds may mediate gastric cytoprotection,Science. 214:200 (1981).PubMedCrossRefGoogle Scholar
  19. 19.
    S. Szabo, and C. Cho, From cysteamine to MPTP: Structure-activity studies with duodenal ulcerogens, Toxicol Pathol. 16:205 (1988).PubMedCrossRefGoogle Scholar
  20. 20.
    G. Glavin, and A. Hall, Brain-gut relationships: Gastric mucosal defense is also important, Acta Physiol Hung. 80:107 (1992).PubMedGoogle Scholar
  21. 21.
    J. Nanoi, R. King, D. Kaplan, and R. Levine, Mechanisms of gastric proton pump inhibition by calcium channel antagonists, J Pharmacol Exp Ther. 252:1102 (1990).Google Scholar
  22. 22.
    T. Godfraind, and S. Govoni, Increasing complexity revealed in regulation of Ca2+ antagonist receptor, Trends Pharmacol Sci. 10:297 (1989).PubMedCrossRefGoogle Scholar
  23. 23.
    G. Glavin, and S. Szabo, Effects of the calcium chelators EGTA and EDTA on ethanol- or stress-induced gastric mucosal lesions and gastric secretions, Eur J Pharmacol. 233:269 (1993).PubMedCrossRefGoogle Scholar
  24. 24.
    R. Mellgren, Calcium-dependent proteases: An enzyme system active at cellular membranes.FASEB J. 1:110 (1987).PubMedGoogle Scholar
  25. 25.
    F. Defeudis, and H. Christen, State- and use-dependent calcium antagonists offer hope in control of GI disorders, Trends Pharmacol Sci. 10:170 (1989).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Gary B. Glavin
  • Arleen M. Hall

There are no affiliations available

Personalised recommendations